89 related articles for article (PubMed ID: 4582564)
1. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
[No Abstract] [Full Text] [Related]
2. Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Bonnet JD; Brownlee RW; Vaitkevicius VK; Talley RW
Cancer Chemother Rep; 1973 Apr; 57(2):231-4. PubMed ID: 4742501
[No Abstract] [Full Text] [Related]
3. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Marsh JC; DeConti RC; Hubbard SP
Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
[No Abstract] [Full Text] [Related]
4. Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Presant CA; Kolhouse JF; Klahr C
Cancer; 1976 Feb; 37(2):620-8. PubMed ID: 1253101
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
van Eden EB; Falkson G; van Dyk JJ; van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Feb; 56(1):107-47. PubMed ID: 5030803
[No Abstract] [Full Text] [Related]
6. Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
Falkson G; van Dyk JJ; van Eden EB; van der Merwe AM; FALKSON HC
Cancer Chemother Rep; 1974; 58(6):939-41. PubMed ID: 4615788
[No Abstract] [Full Text] [Related]
7. Toxicity study of BCNU (NSC-409962) given orally.
Lessner HE; Vogler WR
Cancer Chemother Rep; 1974; 58(3):407-11. PubMed ID: 4601671
[No Abstract] [Full Text] [Related]
8. Combined therapy with cytosine arabinoside (NSC-63878) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for advanced solid tumors.
Kinne DW; Humphrey EW
Cancer Chemother Rep; 1972 Feb; 56(1):53-9. PubMed ID: 5030809
[No Abstract] [Full Text] [Related]
9. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
Ahmann DL; Carr DT; Coles DT; Hahn RG
Cancer Chemother Rep; 1972 Jun; 56(3):401-3. PubMed ID: 19051501
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the management of patients with advanced breast cancer.
Ahmann DL; Hahn RG; Bisel HF
Cancer Chemother Rep; 1972 Feb; 56(1):93-4. PubMed ID: 5030810
[No Abstract] [Full Text] [Related]
11. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
Curtis JE
Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
[No Abstract] [Full Text] [Related]
12. 1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Lokich JJ; Chawla PL; Frei E
Clin Pharmacol Ther; 1975 Mar; 17(3):374-8. PubMed ID: 123490
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
Presant CA; Klahr C; Olander J; Gatewood D
Cancer; 1976 Nov; 38(5):1917-21. PubMed ID: 991105
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Omura GA; Roberts GA
Cancer; 1973 Jun; 31(6):1374-81. PubMed ID: 4709952
[No Abstract] [Full Text] [Related]
15. Combination chemotherapy with adriamycin (NSC-123127) and 1-(2-chloroethyl)-3-cyclohexyl 1-nitrosourea (CCNU; NSC-79037).
Einhorn LH; Livingston RB; Gottlieb JA
Cancer Chemother Rep; 1973; 57(4):437-45. PubMed ID: 4586951
[No Abstract] [Full Text] [Related]
16. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
Rege VB; Owens AH
Cancer Chemother Rep; 1974; 58(3):383-92. PubMed ID: 4601668
[No Abstract] [Full Text] [Related]
17. 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) given alone and combined with antimetabolites in the treatment of advanced solid tumors.
Cohen SM; Weiner MJ; Greenspan EM
Cancer Chemother Rep; 1972 Dec; 56(6):751-4. PubMed ID: 4660631
[No Abstract] [Full Text] [Related]
18. Comparative pharmacokinetics of 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)-1-nitrosourea in rats and patients and extrapolation to clinical trials.
Levin VA; Liu J; Weinkam RJ
Cancer Res; 1981 Sep; 41(9 Pt 1):3475-7. PubMed ID: 7020928
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effect of fluoxymesterone in the treatment of recurrent and progressive breast neoplasms].
Takaya O
Horumon To Rinsho; 1977 Dec; 25(12):1371-84. PubMed ID: 598046
[No Abstract] [Full Text] [Related]
20. Difficulties designing clinical trials as exemplified by a phase 2 drug evaluation of 5(3,3-bis(2-chloroethyl)-1-triazenol)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in patients with disseminated breast cancer.
Ahmann DL; Bisel HF; Hahn RG
Cancer Res; 1973 Jul; 33(7):1707-10. PubMed ID: 4578655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
